Overview

Effect of MK0524A on Flushing Caused by Niacin (0524A-056)

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the effects of MK0524A in reducing flushing associated with niacin.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Niacin
Niacinamide
Nicotinic Acids